Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care... see more

TSXV:COV - Post Discussion

Covalon Technologies Ltd > Time to top up.
View:
Post by bronkrdr on Jun 17, 2020 11:54am

Time to top up.

Are we expweriencing wholesale prices? Hope so!
Comment by familyofficegur on Jun 17, 2020 9:12pm
The company can't turn a profit, can't file their financials, is in breach of debt covenants, has a failed ME strategy...shall I go on? Everyone thinks their tech is worth a pretty penny but why pay up for it now? It looks like more dilution is coming...company has been burning through cash at an alarming rate. I wouldn't add to this until they prove they can operate profitably ...more  
Comment by bronkrdr on Jun 18, 2020 8:09pm
You maybe right, but I'm wondering why Selling General and Admin cost went from $15 M in 2018 to $27M in 2019. Was it expenses for the Saudi deal that went south last year? That's a big jump. Do you think the Covaguad product will help this foundering ship through the debt situation. I'm thinking it will. I've seen some nice testimonials from the medical field about their other ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities